Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström MacroglobulinemiaSteven P. Treon, Jorge J. Castillo, Zachary R. Hunter et al.|Journal of Clinical Oncology|2018Cited by 176
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P. Treon, Jorge J. Castillo, Lian Xu et al.|Journal of Clinical Oncology|2020Cited by 165
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström MacroglobulinemiaSteven P. Treon, Jorge J. Castillo, Kirsten Meid et al.|Journal of Clinical Oncology|2020Cited by 150
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJeremy S. Abramson, Andrew M. Evens, Tatyana Feldman et al.|Annals of Oncology|2014Cited by 138
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemiaLian Xu, Steven P. Treon, Nicholas Tsakmaklis et al.|Blood|2017Cited by 138